Sonnet BioTherapeutics announces adjournment of special meeting

Sonnet BioTherapeutics (SONN) has adjourned its special meeting of stockholders in order to provide stockholders additional time within which to vote on its proposed business combination with Hyperliquid Strategies and Rorschach I, and the other proposals to be considered at the special meeting. As of today, more than 95% of the shares that have been voted on the proposal to approve the Business Combination have been voted in favor. The Company’s Board of Directors continues to believe that all of the proposals contained in the proxy statement are advisable and in the best interests of the Company’s stockholders to consider and act upon. Therefore, the Company adjourned the Special Meeting to allow time to solicit additional votes to meet the required threshold for the transaction approval of a majority of all outstanding shares.